Multiomics study of discarded fresh blastocysts to see patterns linked to chromosomal status
Official title: Prospective Observational Pilot Study of Discarded Blastocysts: a Molecular Approach to Uncovering Hidden Reproductive Potential
Run by Igenomix · NCT07429097 · Data updated 2026-11-12
This study tests whether multiomics patterns in discarded 5–6 day blastocysts relate to chromosomal status to better predict embryo viability for IVF patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 42 Years |
| Sex | Women only |
| Enrollment | 150 (estimated) |
| Sponsor | Igenomix Industry-sponsored |
| Locations | 1 site (Oslo, Oslo) |
| Status | Recruiting |
| Started | March 14, 2026 |
| Main results expected | May 2027 |
| Study ends | May 2027 |
| Registry record updated | November 5, 2026 |
| Trial ID | NCT07429097 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 20–42 undergoing regular IVF/ICSI with fresh blastocyst culture who have at least one discarded day-5/6 blastocyst meeting eligibility and no PGT-M/PGT-SR indication.
✕Probably not a fit
Patients with no discarded blastocysts or with embryos not meeting eligibility criteria may not derive direct benefit from this analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study analyzes fresh, non-vitrified blastocysts that are discarded during IVF to identify multiomics signatures associated with euploid and aneuploid states. Researchers will perform multiomics analyses on these discarded embryos without altering the patients’ planned IVF treatment. The goal is to see if molecular patterns can provide insights beyond traditional morphology and development timing into embryo quality. The study emphasizes that only donated embryos are analyzed and no additional procedures are performed on participants beyond informed consent. Lead sponsor is Igenomix with collaboration from Oslo University Hospital, and the study is conducted at Oslo locations.
Why it matters
Potential benefit: If successful, the findings could improve understanding of embryo viability and guide future selection strategies, potentially reducing unnecessary embryo discard and enhancing IVF success rates.
How similar studies have gone: Previous work using omics has distinguished euploid from aneuploid embryos, but many studies used vitrified embryos; this study is novel in focusing on fresh, non-vitrified blasts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients whose written informed consent approved by the Ethic Committee has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits, and any discomfort involved. * Patients undergoing regular IVF/ICSI cycles with fresh oocytes and embryo culture to the blastocyst stage (day 5-6 after fertilization) * Patients' age will be between 20-42 years of age. * Patients without PGT-M or PGT-SR indication. Exclusion Criteria: * Patients who do not have at least one discarded blastocyst on day 5-6 of development. * Patients with discarded blastocysts that do not meet these criteria: * Presence of ICM * Non-degenerated
Where it's running
-
Oslo University Hospital HF (OUS HF), Rikshospitalet
Oslo, Oslo, Norway Recruiting
Study contacts
- Study coordinator: Carlos Gómez De La Cruz, PhD
- Email: carlos.gomez@vitrolifegroup.com
- Phone: (+34) 963905310
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Differential Granulosa Cell Transcriptome Profiling to Predict Ongoing Pregnancy
Aiming to see if differences in granulosa cell gene activity can predict ongoing pregnancy in IVF and oocyte donation with PGT-A.
-
Detoxify for IVF: Cutting Everyday Pollutants to Help Infertility
This study tests a guide to help IVF patients reduce everyday environmental pollutants and sees if it lowers chemical exposure in urine, blood, and follicular fluid.
-
Carnitine and related supplements before IVF to see if they improve oocytes and embryos
This trial tests whether taking a supplement mix that includes L-carnitine before IVF helps improve the number and quality of eggs and embryos and the chances of pregnancy for women undergoing IVF.
-
Higher or lower starting FSH dose for good-prognosis IVF with PPOS
This trial tests whether starting IVF stimulation with 225 IU or 300 IU of FSH improves oocyte and embryo outcomes in good-prognosis women using PPOS.
-
Environmental and lifestyle factors linked to ART success in infertility patients
This study follows 5,000 infertile men and women to see how environmental exposures and lifestyle relate to the success of assisted reproductive technology.
-
AI tool to analyze sperm and predict their ability to help IVF/ICSI succeed
This project will test an AI platform that analyzes semen samples from men providing sperm for IVF/ICSI to see if it can predict which samples have the best chance of supporting successful IVF/ICSI outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.